"The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dalbavancin 500 mg (Xydalba, Durata Therapeutics) for acute bacterial skin and skin structure infections (ABSSSI) in ad"...
The most frequent adverse event was burning/itching/stinging at the applica-tion site; the incidence and severity of this event were as follows:
|incidence and severity of burning/itching/stinging|
|Product||Total incidence||Maximum severity|
|Luxiq Foam n=63||34 (54%)||28 (44%)||5 (8%)||1 (2%)|
|Betamethasone valerate lotion n=63||33 (52%)||26 (41%)||6 (10%)||1 (2%)|
|Placebo Foam n=32||24 (75%)||13 (41%)||7 (22%)||4 (12%)|
|Placebo Lotion n=30||20 (67%)||12 (40%)||5 (17%)||3 (10%)|
The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximately decreas-ing order of occurrence: irritation; dryness; folliculitis; acneiform eruptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; secondary infection; skin atrophy; striae; and miliaria.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Read the Luxiq (betamethasone valerate foam) Side Effects Center for a complete guide to possible side effects
Last reviewed on RxList: 3/23/2016
Additional Luxiq Information
Luxiq - User Reviews
Luxiq User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.